Vanderbilt-Ingram Cancer Center

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2 Related Genetic Alterations (MK-6482-015)

Read more about Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2 Related Genetic Alterations (MK-6482-015)

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Arul Chinnaiyan, MD, PhD

(Rogel Cancer Center)

is the S.P Hicks Endowed Professor of Pathology and Professor of Urology at the University of Michigan Rogel Cancer Center. He also serves as the Director of the Michigan Center for Translational Pathology and is an Investigator of the Howard Hughes Medical Institute. His research interests focus on functional genomic and bioinformatic approaches to study cancer to understand tumor biology and discover genetic drivers.

(Abramson Cancer Center)

is the Scientific Director of the Abramson Family Cancer Research Institute and an Associate Director of the Cancer Center at the Perelman School of Medicine at the University of Pennsylvania. Her research focuses on how cells sense and respond to changes in the availability of molecular oxygen and nutrients. Her research team is currently studying how O₂ sensing impacts tumor inflammation, metabolism, metastasis and overall disease progression.

(UNC Lineberger Comprehensive Cancer Center)

is an Associate Professor and Vice-Chair of Academic Affairs at the University of North Carolina (UNC) Department of Urology in Chapel Hill. In addition, she is the Director of Urologic Oncology at the UNC Lineberger Comprehensive Cancer Center, where she treats GU malignancies, including bladder, prostate and kidney cancer. She has a background in health services research, and her research interests focus on patient-outcomes research, patient engagement and quality of care for bladder cancer.

(The Francis Crick Institute)

is the Chief Investigator of translational studies into melanoma and kidney cancer and an Independent Group Leader at The Francis Crick Institute. Her research focuses on the development of an evolutionary understanding of cancer for patient benefit. Dr. Turajlic is the Chief Clinical Investigator for the TRACERx Renal study, aiming to map how kidney cancer evolves.

(Rogel Cancer Center)

is a Society of Urologic Oncology (SUO) Fellow at the University of Michigan Rogel Cancer Center. While at the University of Michigan, Dr. Vince also earned a Master’s degree in computational medicine and bioinformatics. His research interests are focused on using precision medicine to combat the concept of racial biology and evaluate the intersectionality of environmental exposures and gene expression on tumor biology.

Genitourinary Cancers

Learn More About Lung Cancer and Lung Cancer Screening:

Screening tests increase the chance of detecting lung cancer early, when it may be easier to treat.

Basic Information about Lung Cancer

Early Detection, Diagnosis, and Staging for Lung Cancer

VUMC Screening Information and Locations

Learn More

What is lung cancer screening?

Lung cancer screening is a test to detect the presence of lung cancer. The test uses low-dose computed tomography (LDCT) i.e. a CT scan, to find nodules in the lungs.

More Information

Who is eligible for lung cancer screening?

You may qualify for screening if you:

are between 50 and 80 years old
if you are a current smoker or quit within the last 15 years
have smoked 20 pack-years or more.
Click here for more infomration.

More Information

How do I know if my insurance covers lung cancer screening?

Most insurance plans and Medicare help pay for recommended lung cancer screening tests.
Check with your doctor to see whether you are eligible and if your insurance will cover lung screening.